BCMA/CD19 CAR T Shows Encouraging Results in R/R Multiple Myeloma | CancerNetwork
Further follow-up is necessary to see if AZD0120 may be preferentially used as a treatment for patients with relapsed/refractory multiple myeloma.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Multiple Myeloma Clinical Trials & Emerging Therapies
- A single‑cell atlas of multiple myeloma defines malignant archetypes and proliferative states
- S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
- Nanomedicine-Empowered CAR‑T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy